Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Genitourinary 1

Conditions

Neoplasms 2Anemia 2Renal Insufficiency, Chronic 1Kidney Failure, Chronic 1

Interventions

fludarabine phosphate 58Cyclophosphamide 54Epoetin Alfa 43Cyclosporine 43Busulfan 43Peripheral Blood Stem Cell Transplantation 39Mycophenolic Acid 34Darbepoetin alfa 33Antilymphocyte Serum 31Whole-Body Irradiation 30Cytarabine 30Filgrastim 29Methotrexate 26Tacrolimus 25Radiotherapy 25Melphalan 24fludarabine 21Methylprednisolone 17Cord Blood Stem Cell Transplantation 17Etoposide 14Granulocyte Colony-Stimulating Factor 13Daunorubicin 13Rivaroxaban 12apixaban 11Thiotepa 11sargramostim 10epoetin beta 10Dalteparin 10eltrombopag 9Alemtuzumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × hematide × Classical hematology × Clear all
NCT00097747 2012-12-21

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

Affymax

Phase 1 Completed
28 enrolled
Classical hematologyGenitourinary

Anemia, Kidney Failure, Chronic, Neoplasms, Renal Insufficiency, Chronic

NCT00272662 2012-12-21

Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

Affymax

Phase 2 Completed
60 enrolled
Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡